NASDAQ: VERV - Verve Therapeutics, Inc.

Yield per half year: +8.37%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Verve Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Verve Therapeutics, Inc.

Verve Therapeutics, Inc., компания по производству генетических лекарств, занимается разработкой препаратов для редактирования генов, предназначенных для пациентов с сердечно-сосудистыми заболеваниями. Его главный кандидат на продукт - VERVE-101, однократное средство для редактирования генов, которое навсегда отключает ген PCSK9 в печени. Компания также участвует в программе разработки ANGPTL3, чтобы навсегда отключить ген ANGPTL3 в печени. У него есть соглашение о сотрудничестве и лицензионное соглашение с Beam Therapeutics; соглашение о разработке и опционе с Acuitas Therapeutics, Inc .

more details
; и лицензионное соглашение Cas9 с The Broad Institute и президентом и научными сотрудниками Гарвардского колледжа. Компания ранее была известна как Endcadia, Inc. и сменила название на Verve Therapeutics, Inc. в январе 2019 года. Verve Therapeutics, Inc. была зарегистрирована в 2018 году и базируется в Кембридже, штат Массачусетс.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-06-17
ISIN US92539P1012
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт https://www.vervetx.com
Цена ао 5.38
Change price per day: -7.96% (5.84)
Change price per week: -8.74% (5.89)
Change price per month: -23.54% (7.03)
Change price per 3 month: -6.85% (5.77)
Change price per half year: +8.37% (4.96)
Change price per year: -59.25% (13.19)
Change price per 3 year: -65.07% (15.39)
Change price per year to date: -4.19% (5.61)
All parameters

Underestimation

Title Value Grade
P/S 80.83 1
P/BV 1.59 8
P/E 6.24 10
EV/EBITDA -3.76 0
Total: 4.75

Efficiency

Title Value Grade
ROA, % -26.58 0
ROE, % -33.37 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.3441 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 505.77 10
Yield Ebitda, % 1508.07 10
Yield EPS, % 186.01 10
Total: 10
More

Institutions Volume Share, %
Alphabet Inc. 12 14.71
Vanguard Group Inc 6 7.54
ARK Investment Management, LLC 6 7.19
Blackrock Inc. 5 6.4
State Street Corporation 5 6.07
T. Rowe Price Investment Management, Inc. 5 5.45
Federated Hermes, Inc. 4 4.24
FMR, LLC 3 4.02
Casdin Capital, LLC 3 3.64
Nikko Asset Management Americas, Inc. 3 3.09

ETFShare, %Profitability for 1 year, %Dividends, %
Virtus LifeSci Biotech Clinical Trials ETF 0.73383 63.04 0.33
Global X Genomics & Biotechnology ETF 0.49685 2.58 0.15585
WisdomTree BioRevolution Fund 0.44376 -29.24 0.78691
SPDR S&P Kensho New Economies Composite ETF 0.09643 -8.65 0.88486
iShares Micro-Cap ETF 0.09357 -13.97 1.54048
Direxion Daily S&P Biotech Bull 3x Shares 0.06928 4067.92 0.25924
Invesco Nasdaq Biotechnology ETF 0.04353 28.58 0.8565
Avantis U.S Small Cap Equity ETF 0.04178 27.77 1.68271
Principal Healthcare Innovators ETF 0.04066 618.5 0.8416
Future Tech ETF 0.04066 426.34 0.8416
Goldman Sachs Innovate Equity ETF 0.04007 29.66 1.20987
Nuveen ESG Small-Cap ETF 0.03159 -14.26 1.41019
ProShares Ultra Nasdaq Biotechnology 0.03074 51.7 0.85651
Vanguard Russell 2000 ETF 0.02 -10.48 1.48801
iShares Morningstar Small-Cap Growth ETF 0.01448 572.1 0.72598
iShares Morningstar Small-Cap Growth ETF 0.01448 33.63 0.72598
Schwab U.S. Small-Cap ETF 0.00902 -10.22 1.51433
ProShares UltraPro Russell2000 0.00796 89.82 1.47873
iShares Morningstar Small-Cap ETF 0.00719 30.1 1.60498
iShares Morningstar Small-Cap ETF 0.00719 391.25 1.60498
Invesco FTSE RAFI US 1500 Small-Mid ETF 0.00612 -10.38 1.75869
SPDR Portfolio MSCI Global Stock Market ETF 0.00532 -3.09 2.19607
Fidelity MSCI Health Care Index ETF 0.00505 -4.29 1.46057
Dimensional U.S. Targeted Value ETF 0.00402 26.01 1.93487
ProShares Hedge Replication ETF 0.0024 5.92 1.47892
Dimensional US Core Equity Market ETF 0.00106 30.98 1.40618
Dimensional U.S. Equity ETF 0.00047 31.53 1.3557
iShares Russell 3000 ETF 0.00044 0.0303 1.43482
Avantis U.S. Equity ETF 0.00043 -4.84 1.59151
Schwab U.S. Broad Market ETF 0.00036 -0.4495 1.43354
Avantis Responsible U.S. Equity ETF 0.00001 26.78 1.45257
Vanguard Russell 3000 ETF 0 31.87 1.43817
0.07202.381.24



Head Job title Payment Year of birth
Dr. Sekar Kathiresan M.D. Co-Founder, CEO & Director 899.55k 1972 (53 years)
Mr. Andrew D. Ashe J.D. President, COO & General Counsel 703.85k 1967 (58 years)
Dr. Anthony Philippakis M.D., Ph.D. Co-Founder & Scientific Advisory Board Member 7.97k
Dr. Kiran Musunuru M.D., M.P.H., Ph.D. Co-Founder N/A
Dr. J. Keith Joung M.D., Ph.D. Co-Founder N/A
Dr. Barry S. Ticho FACC, M.D., Ph.D. Co-Founder N/A 1961 (64 years)
Mr. Issi Rozen M.B.A. Co-Founder & Strategic Advisor N/A
Ms. Allison Dorval CFO & Principal Accounting Officer 260.93k 1976 (49 years)
Dr. Troy Lister Ph.D. Chief Scientific Officer
Ms. Joan Nickerson M.B.A. Chief Administrative Officer 1969 (56 years)

Address: United States, Cambridge, MA , 500 Technology Square - open in Google maps, open in Yandex maps
Website: https://www.vervetx.com